Syncromune® Presents SYNC-T Therapy: Image-Guided Cryolysis and Intratumoral Immunotherapy at CIRSE 2026FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Syncromune®, Inc., a privately held clinical-stage biopharmaceutical company developing SYNC-T™, an investigational in situ multi-target immunotherapy platform for solid tumors, today announced that Stephen Kee, M.D.,...